DK0710121T3 - Fremgangsmåde til behandling af dissemineret sklerose - Google Patents

Fremgangsmåde til behandling af dissemineret sklerose

Info

Publication number
DK0710121T3
DK0710121T3 DK93917954T DK93917954T DK0710121T3 DK 0710121 T3 DK0710121 T3 DK 0710121T3 DK 93917954 T DK93917954 T DK 93917954T DK 93917954 T DK93917954 T DK 93917954T DK 0710121 T3 DK0710121 T3 DK 0710121T3
Authority
DK
Denmark
Prior art keywords
necrosis factor
tumour necrosis
disseminated sclerosis
treating disseminated
factor receptor
Prior art date
Application number
DK93917954T
Other languages
Danish (da)
English (en)
Inventor
John Leslie Turk
David Baker
Marc Feldmann
Original Assignee
Kennedy Inst Of Rheumatology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kennedy Inst Of Rheumatology filed Critical Kennedy Inst Of Rheumatology
Application granted granted Critical
Publication of DK0710121T3 publication Critical patent/DK0710121T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preliminary Treatment Of Fibers (AREA)
  • Transplanting Machines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Spinning Or Twisting Of Yarns (AREA)
  • Treatment Of Fiber Materials (AREA)
  • Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
DK93917954T 1993-07-30 1993-07-30 Fremgangsmåde til behandling af dissemineret sklerose DK0710121T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/GB1993/001614 WO1995003827A1 (en) 1993-07-30 1993-07-30 Method for treating multiple sclerosis

Publications (1)

Publication Number Publication Date
DK0710121T3 true DK0710121T3 (da) 2001-02-05

Family

ID=10729416

Family Applications (1)

Application Number Title Priority Date Filing Date
DK93917954T DK0710121T3 (da) 1993-07-30 1993-07-30 Fremgangsmåde til behandling af dissemineret sklerose

Country Status (11)

Country Link
US (1) US5958409A (es)
EP (2) EP1004312A1 (es)
JP (1) JPH09509646A (es)
AT (1) ATE196849T1 (es)
AU (1) AU4719093A (es)
DE (1) DE69329558T2 (es)
DK (1) DK0710121T3 (es)
ES (1) ES2153384T3 (es)
GR (1) GR3035196T3 (es)
PT (1) PT710121E (es)
WO (1) WO1995003827A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6552170B1 (en) * 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US6270766B1 (en) 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
US7070783B1 (en) * 1995-05-09 2006-07-04 The Mathilda And Terence Kennedy Institute Of Rheumatology Small molecular weight TNF receptor multimeric molecule
US7012060B1 (en) 1995-07-14 2006-03-14 Applied Research Systems Ars Holding N.V. TNF receptor and steroid hormone in a combined therapy
WO1997003686A1 (en) * 1995-07-14 1997-02-06 Applied Research Systems Tnf receptor and steroid hormone in a combined therapy
US7608262B2 (en) 1996-02-16 2009-10-27 The Kennedy Institute Of Rheumatology Methods of preventing or treating thrombosis with tumor necrosis factor antagonists
TW555765B (en) 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
IL127851A0 (en) * 1998-12-30 1999-10-28 Applied Research Systems Inhibition of TNF activity
US6982089B2 (en) 1999-02-24 2006-01-03 Tact Ip, Llc Cytokine antagonists for neurological and neuropsychiatric disorders
US8119127B2 (en) * 1999-02-24 2012-02-21 Tact Ip, Llc Cytokine antagonists for neurological and neuropsychiatric disorders
USRE45976E1 (en) * 1999-02-24 2016-04-19 Tact Ip, Llc Methods of inhibiting the action of TNF for neurological conditions by administering etanercept intrathecally
AU6929100A (en) * 1999-08-23 2001-03-19 Biocrystal Limited Methods and compositions for immunotherapy of b cell involvement in promotion ofa disease condition comprising multiple sclerosis
WO2002096458A1 (en) * 2001-05-30 2002-12-05 Genentech, Inc. Anti-ngf antibodies for the treatment of various disorders
US20050175585A1 (en) * 2001-06-11 2005-08-11 Transition Therapeutics Inc. Combination therapies using vitamin B12 and interferon for treatment of viral proliferative and inflammatory disesases
EP1401483A1 (en) * 2001-06-11 2004-03-31 Transition Therapeutics Inc. Combination therapies using vitamin b12 and therapeutic agents for treatment of viral, proliferative and inflammatory diseases
NZ534125A (en) * 2002-02-20 2006-11-30 Emisphere Tech Inc A formulation comprising a GLP-1 compound and a delivery agent
US9028822B2 (en) 2002-06-28 2015-05-12 Domantis Limited Antagonists against TNFR1 and methods of use therefor
ES2347239T3 (es) 2002-12-02 2010-10-27 Amgen Fremont Inc. Anticuerpos dirigidos al factor de necrosis tumoral y usos de los mismos.
US7101978B2 (en) 2003-01-08 2006-09-05 Applied Molecular Evolution TNF-α binding molecules
US7435799B2 (en) 2004-01-08 2008-10-14 Applied Molecular Evolution TNF-α binding molecules
US8236306B2 (en) * 2004-12-18 2012-08-07 Edward Lewis Tobinick Methods to facilitate transmission of large molecules across the blood-brain, blood-eye, and blood-nerve barriers
US20080317710A1 (en) * 2006-02-22 2008-12-25 University Of Zurich Methods For Treating Autoimmune or Demyelinating Diseases
US8669281B1 (en) 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
NZ631337A (en) 2013-03-14 2017-01-27 Alkermes Pharma Ireland Ltd Prodrugs of fumarates and their use in treating various diseases
AU2015218587B2 (en) 2014-02-24 2017-04-27 Alkermes Pharma Ireland Limited Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL98078A0 (en) * 1991-05-07 1992-06-21 Yeda Res & Dev Pharmaceutical compositions comprising an anticytokyne
DE69027121T3 (de) * 1989-08-07 2001-08-30 Peptech Ltd., Dee Why Bindeligande für tumornekrosisfaktor
EP1132471A3 (de) * 1989-09-12 2001-11-28 F. Hoffmann-La Roche Ag TNF-bindende Proteine
US5656272A (en) * 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
DE4202665A1 (de) * 1992-01-28 1993-07-29 Schering Ag Prostacyclin- und carbacyclinderivate als mittel zur behandlung von multipler sklerose

Also Published As

Publication number Publication date
AU4719093A (en) 1995-02-28
JPH09509646A (ja) 1997-09-30
WO1995003827A1 (en) 1995-02-09
EP0710121A1 (en) 1996-05-08
PT710121E (pt) 2001-04-30
US5958409A (en) 1999-09-28
DE69329558D1 (de) 2000-11-16
GR3035196T3 (en) 2001-04-30
ATE196849T1 (de) 2000-10-15
EP0710121B1 (en) 2000-10-11
ES2153384T3 (es) 2001-03-01
DE69329558T2 (de) 2001-05-31
EP1004312A1 (en) 2000-05-31

Similar Documents

Publication Publication Date Title
DK0710121T3 (da) Fremgangsmåde til behandling af dissemineret sklerose
DK0603305T3 (da) Anvendelse af et thymosin til behandling af hepatitis C
DK0583836T4 (da) Fremgangsmåde til fremstilling af carbonhydridbrændstoffer
BR9305907A (pt) Uso de derivados de substituída para tratamento de esclerose múltipla
MY131298A (en) 5-heteroyl indole derivatives
IT8424009A0 (it) Composizioni analgesiche ed anti-infiammatorie migliorate, comprendente xantine e metodi di utilizzare le stesse.
NO912794D0 (no) Boresystem og fremgangsmaate for styring av retningen paa boringer i grunnformasjoner.
NO179703C (no) Fremgangsmåte for å belegge husholdningsgjenstander med et antivedhengningssjikt, og anvendelse av fremgangsmåten
NO850058L (no) Modifisert kolofoniumharpiks, og fremgangsmaate til fremstilling og anvendelse derav
DK149990D0 (da) Familie af modificerede antistoffer med hoej affinitet til cancerbehandling
IT8967343A0 (it) Anticorpo umano monoclonale ed ibridoma che produce il medesimo
TR27110A (tr) Seramik ve siramik bilesik yapilar üretme yöntemi.
NO910473L (no) Fremgangsmaate for fremstilling av tricykliske aminer.
DK81691D0 (da) Fremgangsmaade til forhindring eller reduktion af eosinofili
ATE155345T1 (de) Gegengift immunsera
DE59207900D1 (de) Iloprost mit wirkung gegen cerebrale malaria
ATE206557T1 (de) Strahlendurchgangspolarisator
ITRM910621A1 (it) Procedimento per la fabbricazione di transistori con struttura gate -isolante -semiconduttore.
DE3878529D1 (de) Vorrichtung zur behandlung von verstauchungen, insbesondere der sprunggelenke sowie zur vermeidung von dabei auftretenden bestimmten komplikationen.
TW350898B (en) Sliding member and manufacture thereof
DE68924495D1 (de) Halbleiter-Bauelement mit verbesserter Gate-Kapazität und dessen Herstellungsverfahren.
DK0730861T3 (da) Anvendelse af 6,7-substituerede 2-aminotetraliner til fremstilling af farmaceutiske præparater, der er nyttige til behandli
DK0766655T3 (da) Fremgangsmåde til fremstilling af et afretningslag
RO86650B1 (ro) Preparat farmaceutic pentru tratarea dermatozelor
KR900702227A (ko) 트랜지스터 점화 시스템의 최종 점화 스테이지